Parikh Anand Kiran 4/A
4/A · Sensei Biotherapeutics, Inc. · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
Sensei (FTH) CEO Anand Parikh Receives Convertible Preferred Awards
What Happened
- Anand K. Parikh, President & CEO and a director of Sensei Biotherapeutics (ticker FTH), received three awards of Series B Non‑Voting Convertible Preferred Stock on February 17, 2026. The reported award amounts were 761.428, 12,320 and 136,884 shares of Series B Preferred (derivative awards). Under the Certificate of Designation each Series B Preferred share is convertible into 1,000 shares of Sensei common stock — i.e., these preferred amounts correspond to approximately 761,428; 12,320,000; and 136,884,000 common‑share equivalents respectively. The awards were issued in connection with the closing of a merger and exchanges of HoldCo common stock and option awards (see footnotes).
Key Details
- Transaction date: February 17, 2026. Report amended: filed June 16, 2026 to correct previously reported counts (original Form 4 filed Feb 19, 2026).
- Price: N/A (derivative/award; no open‑market trade or cash purchase/sale reported).
- Reported awards (Series B Preferred shares): 761.428; 12,320; 136,884.
- Common‑share equivalent (per F1: 1 Series B Preferred = 1,000 Common): ≈761,428; 12,320,000; 136,884,000 common shares respectively.
- Why issued: per footnotes, awards were received in exchange for HoldCo common stock under the Merger Agreement and for certain Faeth (HoldCo) option awards converted in the merger.
- Vesting: some awards are subject to vesting schedules — e.g., earlier option awards vest monthly over 48 months beginning Aug 1, 2022 (F5); another tranche vests monthly beginning Mar 1, 2026 through Jan 1, 2027 with remaining balance vesting Feb 1, 2027 (F7).
- Shares owned after transaction: not specified in this Form 4 amendment.
- Filing note: This is an amended Form 4 correcting previously reported option and preferred share counts.
Context
- These entries are derivative awards tied to a corporate merger and option conversions, not open‑market buys or sales. Because Series B Preferred shares are convertible into large numbers of common shares (1,000:1), the reported preferred‑share counts translate into large common‑share equivalents — but many shares may be subject to vesting and conversion conditions. The amendment simply corrects previously reported quantities; it does not by itself indicate a buy/sell trading signal.
Insider Transaction Report
Form 4/AAmended
Parikh Anand Kiran
DirectorPresident and CEO
Transactions
- Award
Series B Preferred Stock
[F1][F2][F3]2026-02-17+761.428→ 761,428 total→ Common Stock (761,428 underlying) - Award
Employee Stock Option (right to buy)
[F4][F5]2026-02-17+12,320→ 12,320 totalExercise: $1.16Exp: 2032-09-14→ Common Stock (12,320 underlying) - Award
Employee Stock Option (right to buy)
[F6][F7]2026-02-17+136,884→ 136,884 totalExercise: $1.16Exp: 2025-11-30→ Common Stock (136,884 underlying)
Footnotes (7)
- [F1]Each share of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the "Company"). The Preferred Stock has no expiration date.
- [F2]Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. ("HoldCo") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").
- [F3]Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock ("Common Stock").
- [F4]Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.
- [F5]Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
- [F6]Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.
- [F7]Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027.
Signature
/s/ Anand Kiran Parikh|2026-06-16